12 min

Evaluating the Effectiveness of Bivalent COVID-19 Vaccines in Children and Adolescents Coronavirus (COVID-19) Q&A

    • Medicine

Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents.

Related Content:
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents.

Related Content:
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

12 min

More by JAMA Network

JAMAevidence JAMA Guide to Statistics and Methods
JAMA Network
JAMA Neurology Author Interviews
JAMA Network
JAMA Clinical Reviews
JAMA Network
Coronavirus (COVID-19) Q&A
JAMA Network
JAMA Network Open Conversations
JAMA Network
JAMAevidence Users' Guides to the Medical Literature
JAMA Network